SANA Fundamental Analysis - SANA BIOTECHNOLOGY INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to SANA. SANA was compared to 538 industry peers in the Biotechnology industry. SANA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SANA has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

SANA had negative earnings in the past year.

In the past year SANA has reported a negative cash flow from operations.

In the past 5 years SANA always reported negative net income.

SANA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

SANA has a worse Return On Assets (-69.73%) than 61.74% of its industry peers.

SANA's Return On Equity of -205.77% is on the low side compared to the rest of the industry. SANA is outperformed by 67.65% of its industry peers.

		Industry Rank	Sector Rank
ROA	-69.73%
ROE	-205.77%
ROIC	N/A

ROA(3y)-45.37%

ROA(5y)-41.34%

ROE(3y)-86.33%

ROE(5y)-74.79%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

SANA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for SANA has been increased compared to 1 year ago.

SANA has more shares outstanding than it did 5 years ago.

There is no outstanding debt for SANA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -6.63, we must say that SANA is in the distress zone and has some risk of bankruptcy.

SANA has a Altman-Z score of -6.63. This is in the lower half of the industry: SANA underperforms 65.80% of its industry peers.

There is no outstanding debt for SANA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-6.63

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 2.47 indicates that SANA has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 2.47, SANA is doing worse than 69.69% of the companies in the same industry.

A Quick Ratio of 2.47 indicates that SANA has no problem at all paying its short term obligations.

SANA has a worse Quick ratio (2.47) than 67.47% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.47
Quick Ratio	2.47

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SANA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.27%, which is quite good.

EPS 1Y (TTM)19.27%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%0%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 5.90% on average over the next years.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y23.19%

EPS Next 2Y17.93%

EPS Next 3Y10.39%

EPS Next 5Y5.9%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SANA. In the last year negative earnings were reported.

Also next year SANA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y17.93%

EPS Next 3Y10.39%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

SANA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SANA BIOTECHNOLOGY INC

NASDAQ:SANA (9/19/2025, 8:00:02 PM)

After market: 3.1 +0.01 (+0.32%)

3.09

-0.2 (-6.08%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-11 2025-08-11/amc

Earnings (Next)11-06 2025-11-06/amc

Inst Owners86.94%

Inst Owner Change-2.35%

Ins Owners8.27%

Ins Owner Change0.11%

Market Cap761.25M

Analysts84.29

Price Target8.84 (186.08%)

Short Float %13.34%

Short Ratio5.55

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)5.4%

Min EPS beat(2)0.47%

Max EPS beat(2)10.32%

EPS beat(4)4

Avg EPS beat(4)5.41%

Min EPS beat(4)0.47%

Max EPS beat(4)10.32%

EPS beat(8)6

Avg EPS beat(8)12.12%

EPS beat(12)9

Avg EPS beat(12)9.29%

EPS beat(16)12

Avg EPS beat(16)8.83%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-7.14%

PT rev (3m)-7.14%

EPS NQ rev (1m)2.97%

EPS NQ rev (3m)10.74%

EPS NY rev (1m)0%

EPS NY rev (3m)-13.98%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	6.21
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.88

EYN/A

EPS(NY)-0.71

Fwd EYN/A

FCF(TTM)-0.75

FCFYN/A

OCF(TTM)-0.73

OCFYN/A

SpS0

BVpS0.5

TBVpS-0.31

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-69.73%
ROE	-205.77%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-45.37%

ROA(5y)-41.34%

ROE(3y)-86.33%

ROE(5y)-74.79%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	28.01%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.47
Quick Ratio	2.47
Altman-Z	-6.63

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)135.8%

Cap/Depr(5y)216.07%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)19.27%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%0%

EPS Next Y23.19%

EPS Next 2Y17.93%

EPS Next 3Y10.39%

EPS Next 5Y5.9%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y14.57%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year29.69%

EBIT Next 3Y4.5%

EBIT Next 5YN/A

FCF growth 1Y36.47%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y35.2%

OCF growth 3YN/A

OCF growth 5YN/A

SANA BIOTECHNOLOGY INC (SANA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens